STEVENSON, Md., Aug. 22, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of purchasers of Envision Healthcare Corporation (NYSE:EVHC) (“Envision” or the “Company”) securities during the period between March 2, 2015 and July 21, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until October 3, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Envision securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Envision’s operating subsidiary, EmCare Holdings, Inc. (“EmCare”), routinely arranged for patients who sought treatment at in-network facilities to be treated by out-of-network physicians, EmCare accordingly billed these patients at higher rates than if the patients had received treatment from in-network physicians, and EmCare revenues were likely to be unsustainable after the conduct came to light.
According to the complaint, following a July 24, 2017 article about the billing practices, the value of Envision shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Envision securities purchased on or after March 2, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58%
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 



